Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Apatinib in Advanced ICC
NCT04454905Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04454905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04454905.